Solara Active Pharma Sciences quarterly results and financials

Solara Active Pharma Sciences (SOLARA)₹648.05−0.99%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Sep 2026 quarter (consolidated), Solara Active Pharma Sciences reported sales of ₹418 Cr, up 32.8% from Sep 2025, and net profit of ₹27.91 Cr. For the year to Mar 2026, sales were ₹1,374 Cr and net profit −₹6.98 Cr.

Sales (Sep 2026): ₹418 Cr
Net profit (Sep 2026): ₹27.91 Cr
Sales (FY Mar 2026): ₹1,374 Cr
Net profit (FY Mar 2026): −₹6.98 Cr
EPS (Sep 2026): ₹5.85
Borrowings (Mar 2026): ₹687 Cr

Company filings, consolidated accounts; latest reported quarter Sep 2026

Solara Active Pharma Sciences quarterly results

₹ crore unless stated; each column is a quarter.

Solara Active Pharma Sciences Quarterly results
	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	213	300	364	348	301	274	320	315	350	388	383	418
Expenses	375	291	323	287	244	228	263	280	313	331	321	341
Operating Profit	−162	10.01	42.06	61.02	58.01	45.04	57.04	35.01	37.04	58.05	61.99	77.01
OPM %	−76.0%	3.3%	12.0%	18.0%	19.0%	16.9%	18.0%	11.0%	11.0%	15.0%	16.0%	18.0%
Other Income	−62.17	−121	1.01	0.00	1.01	6.02	1.01	0.00	−7.03	6.02	3.01	−4.02
Interest	24.97	30.96	30.95	27.95	26.96	28.94	23.97	20.96	21.98	27.98	21.96	17.98
Depreciation	25.97	24.96	24.96	24.97	24.95	23.97	23.95	23.98	25.96	25.95	26.95	26.96
Profit before tax	−275	−167	−12.99	7.99	7.99	−1.99	10.98	−9.99	−16.99	9.98	15.97	27.96
Tax %	0.0%	53.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Exceptional items	−63.26	−57.19	0.00	0.00	0.00	0.00	0.00	0.00	−7.02	1.01	0.00	−4.01
Net Profit	−274	−254	−12.95	7.97	7.97	−1.99	10.97	−9.97	−16.95	9.97	15.95	27.91
EPS (Rs)	−57.31	−53.13	−3.73	2.21	2.23	−0.57	2.90	−2.78	−4.81	2.64	3.37	5.85

Solara Active Pharma Sciences profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Solara Active Pharma Sciences Profit and loss
	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	523	1,391	1,326	1,622	1,271	1,449	1,293	1,287	1,374	1,541
Expenses	465	1,177	1,065	1,235	1,192	1,313	1,387	1,079	1,186	1,306
Operating Profit	57.03	213	260	386	81.12	134	−95.13	206	187	234
OPM %	11.0%	15.0%	20.0%	24.0%	6.0%	9.0%	−7.0%	15.9%	14.0%	15.2%
Other Income	2.01	12.04	27.12	29.10	16.04	22.07	−186	8.03	0.00	−2.02
Interest	24.97	81.93	77.93	83.89	74.91	89.87	105	115	94.92	89.90
Depreciation	33.93	82.93	93.89	109	112	111	103	98.86	99.82	106
Profit before tax	0.00	59.89	115	222	−90.90	−44.98	−488	0.99	−6.99	36.92
Tax %	−70.0%	1.0%	0.0%	0.0%	−36.0%	−50.0%	16.0%	0.0%	0.0%	—
Exceptional items	−1.01	0.00	0.00	2.01	−4.01	0.00	−160	0.00	−6.02	−10.02
Net Profit	0.00	58.82	115	220	−57.75	−21.93	−565	0.99	−6.98	36.88
EPS (Rs)	—	17.27	31.95	46.17	−12.09	−4.61	−118.05	0.14	−2.04	7.05
Dividend payout %	0.0%	22.0%	5.0%	11.1%	0.0%	−49.0%	0.0%	0.0%	0.0%	—

Solara Active Pharma Sciences balance sheet

₹ crore, at each year end.

Solara Active Pharma Sciences Balance sheet
	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	24.90	25.92	26.89	35.86	35.87	35.85	35.85	39.83	44.85
Reserves	739	930	1,060	1,554	1,488	1,464	898	1,054	1,209
Borrowings	634	539	722	621	1,037	1,013	1,013	796	687
Other Liabilities	424	464	346	402	381	384	405	341	391
Total Liabilities	1,821	1,959	2,153	2,612	2,942	2,896	2,351	2,230	2,331
Fixed Assets	1,087	1,219	1,398	1,383	1,357	1,364	1,269	1,193	1,238
CWIP	70.93	39.95	39.95	88.01	239	238	256	280	205
Investments	1.01	0.00	0.00	0.00	0.00	2.01	2.01	2.01	5.02
Other Assets	662	699	715	1,141	1,347	1,292	824	755	884
Inventories	188	214	280	295	577	559	361	318	318
Trade receivables	263	289	227	483	490	537	349	327	439
Cash & equivalents	47.18	76.28	57.26	200	47.19	9.03	9.04	4.01	50.22
Total Assets	1,821	1,959	2,153	2,612	2,942	2,896	2,351	2,230	2,331

Solara Active Pharma Sciences cash flow

₹ crore, for each year.

Solara Active Pharma Sciences Cash flow
	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	48.93	166	241	155	−241	156	109	212	153
Cash from investing activity	−84.85	−113	−358	−106	−243	−80.89	−3.99	−36.94	−98.80
Cash from financing activity	68.09	−23.01	97.14	92.05	334	−113	−106	−180	−54.06
Net cash flow	30.95	29.93	−19.97	142	−151	−37.96	0.00	−3.99	0.99
Capex	35.14	59.19	270	175	210	111	41.11	40.13	53.17
Free cash flow	14.05	108	−25.07	−16.05	−452	46.17	69.22	174	101
CFO / OP %	92.0%	85.0%	103.0%	49.0%	−277.0%	106.0%	−113.0%	104.0%	83.0%

Solara Active Pharma Sciences ratios

Working-capital days and returns, by year.

Solara Active Pharma Sciences Ratios
	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	184	76	63	109	141	136	99	93	117
Inventory days	252	111	170	149	321	258	163	185	170
Days payable	420	127	132	156	154	142	142	144	146
Cash conversion cycle	16	60	101	102	308	252	120	134	140
Working capital days	−124	−22	−32	16	37	20	−128	−62	−24
ROCE %	—	10.1%	12.1%	15.1%	0.0%	2.0%	−8.9%	6.0%	5.0%

Solara Active Pharma Sciences: frequently asked questions

What are the latest quarterly results of Solara Active Pharma Sciences?

For the Sep 2026 quarter, Solara Active Pharma Sciences reported sales of ₹418 Cr, up 32.8% year on year and net profit of ₹27.91 Cr. The operating margin was 18.0%.

What is the annual revenue of Solara Active Pharma Sciences?

Solara Active Pharma Sciences' sales for the year to Mar 2026 were ₹1,374 Cr; over the last twelve months they were ₹1,541 Cr.

What is the net profit of Solara Active Pharma Sciences?

Net profit for the year to Mar 2026 was −₹6.98 Cr, and ₹36.88 Cr over the last twelve months. Earnings per share over the same trailing period were ₹7.05.

How much debt does Solara Active Pharma Sciences have?

Solara Active Pharma Sciences reported borrowings of ₹687 Cr at Mar 2026, against cash and equivalents of ₹50.22 Cr.

What is the free cash flow of Solara Active Pharma Sciences?

Cash from operations was ₹153 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹101 Cr.

Loading…